Developer of T cell therapeutics designed to cure autoimmune and degenerative diseases.
Developer of T cell therapeutics designed to cure autoimmune and degenerative diseases.
Drug Discovery📍 San Francisco, CAFounded 2019
Current Valuation
$715M
as of 2023-Q1
PRIVATE
QL Price
$715M
0% vs last round
QuantLogix's current estimate for Sonoma Biotherapeutics, published 2026-11-12 — in line with the last disclosed round of $715M (2023-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$715M
2023-Q1
weight 0.08
How this price has held up
No round has priced for Sonoma Biotherapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-11-12 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Sonoma Biotherapeutics, 2026-11-12 (be3a9235847b3d4a).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Sonoma Biotherapeutics going public?
No. Sonoma Biotherapeutics is private and has not filed to go public. There is no S-1 on file.
What is Sonoma Biotherapeutics' valuation in 2026?
Sonoma Biotherapeutics is valued at $715M as of 2023-Q1, set by its Series B1 ($30M, Mar 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Sonoma Biotherapeutics filed an S-1?
No public S-1 is on file for Sonoma Biotherapeutics.
How much has Sonoma Biotherapeutics raised?
Sonoma Biotherapeutics has raised $365.1M in total, most recently a Series B1 of $30M in Mar 2023.
Is Sonoma Biotherapeutics publicly traded — can you buy Sonoma Biotherapeutics stock?
No. Sonoma Biotherapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Sonoma Biotherapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Name-verified against lead sponsor "Sonoma Biotherapeutics, Inc." on ClinicalTrials.gov as of 2026-11-12. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▼ Hiring downtrend
-55% vs 2026-09
Open roles
5
via careers page
Product-build share
40%
engineering, research, product, design
Trajectory
tightening
balanced build + GTM — 40% builders vs 60% go-to-market/G&A — scaling both sides.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Sononma Icons Medical, Dental, Vision InsuranceMedical, Dental, and Vision InsuranceSkip to content[Partnerships](https://sonomabio.com/partnerships/ "Partnerships")A Message from SonomaBio’s Talent Acquisition Team
Counted from Sonoma Biotherapeutics's live job board as of 2026-10-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyLife ScienceTherapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q1. Refreshed quarterly.